Previously submitted to: Interactive Journal of Medical Research (no longer under consideration since Jan 24, 2024)
Date Submitted: Apr 16, 2023
Open Peer Review Period: Apr 16, 2023 - Jun 11, 2023
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Cancer stem cells and the future of cancer therapy
ABSTRACT
The Cancer Stem Cell (CSC) Model postulates that there are two distinct groups of cells within a tumour: those that can self-replicate, give rise to and sustain cancers and those that cannot. Experiments largely support this model especially in the case of leukaemias. It is important to note, however, that there are some controversies especially regarding transplantation experiments that have cast doubts over aspects of the model. The CSC model provides an explanation to many phenomena including drug resistance, relapse and metastasis. The role of CSCs in these processes means that they are an interesting therapeutic target. Studies have investigated markers that could be used to identify them, the pathways they employ and potential ways that they can be targeted. Treatments targeting CSCs have shown promising results, especially in combatting relapse. We will examine the broad field of CSCs, explaining their implications and potential in therapy. Importantly, however, the field is huge and of necessity, selected examples will be discussed to highlight the general applicability of the CSC concept.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.